Multiple BACE1 inhibitors abnormally increase the BACE1 protein level in neurons by prolonging its half-life

Abstract

There is keen interest in elucidating the biological mechanisms underlying recent failures of β‐site amyloid precursor protein–cleaving enzyme‐1 (BACE1) inhibitors in Alzheimer s disease trials.